Enabling Precision Immunology

ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases. We are employing our massively parallel, multiplexed, and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease.


Management Team

Christoph Westphal, MD PhD
Executive Chair, ImmuneID Partner, Longwood Fund
Lea Hachigian, PhD

Founding CEO, BOD
Principal, Longwood Fund

Jeff Capello, MBA

Ittai Harel, MBA

ImmuneID, BOD
Managing Partner, Pitango

Peter Hutt, JD

GC, ImmuneID BOD
Senior Counsel, Covington & Burling LLP
Thomas Haag, JD PhD

GC, ImmuneID
Co-founder/CEO/GC PhosImmune

Lucy Liu, PhD

Head of Strategy, ImmuneID
Senior Associate
Longwood Fund


Steve Elledge, PhD
Tomasz Kula, PhD
H. Benjamin Larman, PhD
Michael Mina, MD PhD
Kari Nadeau, MD PhD
Chris Walsh, PhD
David Walt PhD



The Prudential Tower
800 Boylston Street Suite 1555
Boston, MA, 02199


©2021 ImmuneID, Inc.